



FOR IMMEDIATE RELEASE

February 27, 2014

Forward Science Technologies & Resolution Biomedical Partner to Launch Liquid-Cytology Testing for Dental Industry

Forward Science Technologies is the first American company to incorporate fluorescence technology and liquid-based cytology to enhance the oral health assessment.

HOUSTON, TEXAS - Forward Science Technologies LLC, manufacturer of OralID™, the latest oral cancer screening device, announces the launch of CytID™, a liquid-based cytology method for sampling tissue highlighted by OralID. CytID incorporates technology from Resolution Biomedical, Inc., makers of ClearPrep, next generation liquid-based cytology.

"OralID users have been asking us to develop a test for suspicious tissue highlighted by the fluorescence technology," explained Dr. Brian Pikkula, president & CTO of Forward Science Technologies, "incorporating a high-quality liquid-based product enhances the entire screening process."

"We have been testing ClearPrep for oral screening for some time," explained Michael Friedl, President & CEO of Resolution Biomedical. "Because of their depth of experience in the dental market, partnering with Forward Science Technologies has been a natural fit for us. We have high hopes for CytID."

In addition to being registered with the US FDA & CE Marked, ClearPrep Next-Generation Liquid-Based Cytology has been validated for all types of cytology, which is used to test for certain types of cancer, including cervical, oral, bladder, thyroid, among others. ClearPrep has also been validated on leading molecular-based HPV/STI testing platforms. ClearPrep features a unique



patented sample collection vial that improves patient outcomes by increasing cellularity of samples at the point of collection.

Please see www.clearprepcytology.com for further information and distribution contacts.

About Resolution Biomedical, Inc.

Resolution Biomedical was founded in 2009 to develop and launch ClearPrep Next-Generation Liquid-Based Cytology. ClearPrep is used by medical testing laboratories for preparation of samples for screening of several types of cancer. It is currently available in the United States and multiple countries around the world. The company is licensed by the California Department of Public Health, is ISO 13485 certified and its facility has been registered with the US FDA.

Contact: Terence Lynch
tlynch@rbimed.com

About Forward Science Technologies LLC

Forward Science Technologies manufactures and markets the OralID, a fluorescence based screening device, which highlights oral mucosal abnormalities including cancerous and dysplastic lesions. The kit includes the SmartFilterID for clinical photo documentation, a two year warranty, and free lifetime Team Training. The OralID kit is priced less than one-half of the other fluorescence based oral cancer screening devices on the market, and is the only device that requires no disposables. For more information, visit www.cyt-id.com

Contact: Robert Whitman
info@cyt-id.com

###